News

AFT Completes Pascomer Clinical Study and Takes Back Rights in North America

AFT Pharmaceuticals announces the analysis of its study examining its medicine Pascomer as a topical treatment for facial angiofibromas (FA) associated with Tuberous Sclerosis Complex (TSC).

Read More

Dr Doug Wilson to step down from AFT Board

AFT Pharmaceuticals today announces that Dr Doug Wilson will step down from its Board of Directors

Read More

AFT and RooLife launch OTC medicines online in China

AFT Pharmaceuticals and RooLife Group today announce they have launched a range of AFT’s over the counter (OTC) pharmaceuticals through their store on the China Cross Border E-Commerce (CBEC) online platform Tmall Global.

Read More

AFT Sponsors APP Conference 2022 with Crystawash Extend

AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.

Read More

AFT Pharmaceuticals partners with Farmaforce

Farmaforce, an award-winning contract sales organisation offering innovative solutions to the Australian pharmaceutical industry, today confirmed its formal partnership with AFT Pharmaceuticals (AFT) to provide “best in class” representation to healthcare practitioners and professionals.

Read More

AFT launches preservative-free antibacterial eye drop Ocuzo

AFT Pharmaceuticals has opened a new front in its eye drop portfolio, with the introduction of a preservative-free product called Ocuzo for bacterial eye infections.

Read More

New clinical study shows Novaliq NovaTears® +Omega-3 eye drops is significantly effective treatment for dry eye disease.

NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.

Read More

Maxigesic® Oral Liquid gets first regulatory approval

Maxigesic Oral Liquid – a non-opioid analgesic developed for children – achieves first approval in Europe to set up the first global launch and a pathway for further registrations and launches.

Read More

AFT at APP 2021

AFT Pharmaceuticals participate in the Australian Pharmacy Professional (APP) Conference and Trade Exhibition in May 2021.

Read More

AFT extends Maxigesic® IV license in South America

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has licensed Maxigesic IV into Colombia, Peru, Chile, Ecuador, Bolivia, and Uruguay, extending the medicine’s addressable market in Latin America and the Caribbean to 17 countries.

Read More

AFT licenses Maxigesic® IV in the US

AFT Pharmaceuticals announces it has signed an exclusive License and Distribution Agreement with Hikma Pharmaceuticals USA (“Hikma”) for the commercialisation of its Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine, in the United States.

Read More

AFT licenses Pascomer for Europe

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®

Read More